Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Shares Issued (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Shares Issued for 4 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 65.44% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.9 million through Dec 2025, up 112.06% year-over-year, with the annual reading at $67.9 million for FY2025, 66.5% up from the prior year.
  • Shares Issued hit $5.7 million in Q4 2025 for Axsome Therapeutics, down from $9.9 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $243.4 million in Q3 2022 to a low of $176000.0 in Q2 2022.
  • Historically, Shares Issued has averaged $45.3 million across 4 years, with a median of $13.1 million in 2024.
  • Biggest YoY gain for Shares Issued was 119956.82% in 2023; the steepest drop was 86.13% in 2023.
  • Year by year, Shares Issued stood at $243.4 million in 2022, then plummeted by 86.13% to $33.8 million in 2023, then crashed by 51.35% to $16.4 million in 2024, then plummeted by 65.44% to $5.7 million in 2025.
  • Business Quant data shows Shares Issued for AXSM at $5.7 million in Q4 2025, $9.9 million in Q3 2025, and $32.6 million in Q2 2025.